MedTrace Logo

Can Contrast-Enhanced Spectral Mammography Improve the Accuracy of a Diagnosis

NCT03929822 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2023-01-20

No results posted yet for this study

Summary

The purpose of this study is to test whether contrast-enhanced spectral mammography (CESM) may be able to reduce the number of unnecessary biopsies in women whose screening mammograms had abnormal findings.

Conditions

  • Breast Screening

Interventions

DIAGNOSTIC_TEST

Contrast-Enhanced Spectral Mammography

A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.

Sponsors & Collaborators

Principal Investigators

  • Janice Sung, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
30 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-23
Primary Completion
2023-01-19
Completion
2023-01-19
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03929822 on ClinicalTrials.gov